Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–114 of 114 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: metformin hydrochloride 500 mg tablet Clear all

Conditions: Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Metformin, saxagliptin, AZD9668, placebo; Drug
Lead sponsor: Nick Giannoukakis, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin 500 mg tablet; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Hyperemesis Gravidarum
Interventions: Metformin Extended Release Oral Tablet; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Birmingham, Alabama • Los Angeles, California

Conditions: Interaction, Endogenous Biomarkers
Interventions: MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product, Probenecid 500 MG; Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Stage IV Pancreatic Cancer
Interventions: Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI; Drug · Genetic
Lead sponsor: Pancreatic Cancer Research Team; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 5
States / cities: Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more

Conditions: Diabetes Mellitus, Type 2, Diabetes
Interventions: Metformin, Detemir, Liraglutide, Insulin Aspart; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: PCOS
Interventions: Metformin and Spironolactone; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Covid19
Interventions: Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 10,956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 110
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more

Conditions: Healthy
Interventions: Metformin Hydrochloride ER Tablets 500 mg, Glucophage® XR 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Interventions: Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endometrial Cancer
Interventions: Metformin, Letrozole, Everolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 6
States / cities: Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more

Conditions: Diabetes
Interventions: Saxagliptin, Placebo, metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 51
States / cities: Columbiana, Alabama • Haleyville, Alabama • Mesa, Arizona + 45 more

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Dapagliflozin placebo, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 38
States / cities: Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more

Conditions: Healthy
Interventions: Metformin Hydrochloride ER Tablets 500 mg, Glucophage® XR Tablets 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 79
States / cities: Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more

Search by objective public record fields.

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Metformin Treatment in Progressive Multiple Sclerosis

Pharmacogenetics of Metformin Action in PCOS

Hyperemesis Gravidarum Risk Reduction With Metformin

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

Metabolic and Neuro-Endocrine Effect of Treating PCOS in Adolescents

ACTIV-6: COVID-19 Study of Repurposed Medications

Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone